癌症研究
埃罗替尼
医学
免疫系统
肿瘤科
比例危险模型
免疫疗法
体细胞
基因
食管鳞状细胞癌
肿瘤微环境
小RNA
内科学
生存分析
CD38
食管癌
生物
发病机制
转录组
基因表达谱
肿瘤进展
血管生成
单变量分析
癌
林恩
E2F1
癌症
作者
Chao Jiang,Meng Shen,Jing Zhu,Xiu Zhang,Kai Chen
标识
DOI:10.1097/cji.0000000000000587
摘要
SUMMARY: Ubiquitin-proteasome system (UPS) is implicated in pathogenesis and progression of esophageal squamous cell carcinoma (ESCC), representing a promising therapeutic target. However, clinical significance of UPS in ESCC remains incompletely elucidated. UPS genes associated with ESCC survival were first screened through univariate Cox regression analysis. Consensus clustering was performed on TCGA-ESCC cohort based on these genes. Functional enrichment, tumor immune microenvironment analysis, and somatic mutation profiling were conducted for different clusters. Potential therapeutics and biomarkers were evaluated, and miRNA-TF-hub gene regulatory network was constructed. ESCC samples were stratified into 2 distinct clusters (cluster 1 and cluster 2), with cluster 1 demonstrating superior overall survival. Differential analysis revealed enrichment in cell adhesion and calcium signaling pathways. Immune infiltration analysis indicated elevated CD8+ T cells, mast cells, neutrophils, and TILs in cluster 2, alongside lower TIDE scores. TP53 exhibited the highest mutation frequency (93% vs. 86% in cluster 1 vs. cluster 2). Selumetinib, entinostat, and erlotinib were identified as candidate drugs for cluster 2, whereas tozasertib, alpelisib, and cediranib showed higher suitability for cluster 1. Ten potential biomarkers, 13 transcription factors, and 2 miRNAs were characterized. This study elucidates the role of UPS in ESCC progression and provides a framework for personalized treatment strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI